Festuccia, Claudio <br/><br/>
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.  [electronic resource] 

 -  Endocrine-related cancer  Jun 2009 
 - 401-13 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1351-0088 
<br/><br/><label>Standard No.: </label>10.1677/ERC-08-0130  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Azacitidine--therapeutic use<br/>Blotting, Western<br/>Caspase 3--metabolism<br/>Cell Proliferation--drug effects<br/>Cisplatin--administration & dosage<br/>Cyclin D1--metabolism<br/>Cyclin-Dependent Kinase Inhibitor p16--metabolism<br/>Cyclin-Dependent Kinase Inhibitor p21--metabolism<br/>Cyclin-Dependent Kinase Inhibitor p27--metabolism<br/>Disease Models, Animal<br/>Docetaxel<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Flow Cytometry<br/>Humans<br/>Male<br/>Mice<br/>Mice, Nude<br/>Prostatic Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Signal Transduction<br/>Taxoids--administration & dosage<br/>Xenograft Model Antitumor Assays<br/>bcl-2 Homologous Antagonist-Killer Protein--metabolism<br/>bcl-2-Associated X Protein--metabolism